CNS Drugs

, Volume 27, Issue 2, pp 135–153 | Cite as

Potential Mechanisms of Action of Lithium in Bipolar Disorder

Current Understanding
  • Gin S. MalhiEmail author
  • Michelle Tanious
  • Pritha Das
  • Carissa M. Coulston
  • Michael Berk
Review Article


Lithium has been used for over half a century for the treatment of bipolar disorder as the archetypal mood stabilizer, and has a wealth of empirical evidence supporting its efficacy in this role. Despite this, the specific mechanisms by which lithium exerts its mood-stabilizing effects are not well understood. Given the inherently complex nature of the pathophysiology of bipolar disorder, this paper aims to capture what is known about the actions of lithium ranging from macroscopic changes in mood, cognition and brain structure, to its effects at the microscopic level on neurotransmission and intracellular and molecular pathways. A comprehensive literature search of databases including MEDLINE, EMBASE and PsycINFO was conducted using relevant keywords and the findings from the literature were then reviewed and synthesized. Numerous studies report that lithium is effective in the treatment of acute mania and for the long-term maintenance of mood and prophylaxis; in comparison, evidence for its efficacy in depression is modest. However, lithium possesses unique anti-suicidal properties that set it apart from other agents. With respect to cognition, studies suggest that lithium may reduce cognitive decline in patients; however, these findings require further investigation using both neuropsychological and functional neuroimaging probes. Interestingly, lithium appears to preserve or increase the volume of brain structures involved in emotional regulation such as the prefrontal cortex, hippocampus and amygdala, possibly reflecting its neuroprotective effects. At a neuronal level, lithium reduces excitatory (dopamine and glutamate) but increases inhibitory (GABA) neurotransmission; however, these broad effects are underpinned by complex neurotransmitter systems that strive to achieve homeostasis by way of compensatory changes. For example, at an intracellular and molecular level, lithium targets second-messenger systems that further modulate neurotransmission. For instance, the effects of lithium on the adenyl cyclase and phospho-inositide pathways, as well as protein kinase C, may serve to dampen excessive excitatory neurotransmission. In addition to these many putative mechanisms, it has also been proposed that the neuroprotective effects of lithium are key to its therapeutic actions. In this regard, lithium has been shown to reduce the oxidative stress that occurs with multiple episodes of mania and depression. Further, it increases protective proteins such as brain-derived neurotrophic factor and B-cell lymphoma 2, and reduces apoptotic processes through inhibition of glycogen synthase kinase 3 and autophagy. Overall, it is clear that the processes which underpin the therapeutic actions of lithium are sophisticated and most likely inter-related.


Lithium Bipolar Disorder NMDA Receptor Grey Matter Volume cAMP Response Element Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Gin S. Malhi has received research support from AstraZeneca, Eli Lilly, Organon, Pfizer, Servier and Wyeth; has been a speaker for AstraZeneca, Eli Lilly, Janssen-Cilag, Lundbeck, Pfizer, Ranbaxy, Servier, and Wyeth; and has been a consultant for AstraZeneca, Eli Lilly, Janssen-Cilag, Lundbeck and Servier. Michael Berk has received research support from the Medical Benefits Fund of Australia, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma and Servier; has been a speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck, Pfizer, Sanofi-Synthelabo, Servier, Solvay and Wyeth; and has served as a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck and Servier. Michelle Tanious, Pritha Das and Carissa M. Coulston have no conflicts of interests or funding to declare. This work was supported by a National Health and Medical Research Council program grant (510135).


  1. 1.
    Malhi GS, Gershon S. Ion men and their mettle. Aust N Z J Psychiatry. 2009;43:1091–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10(2):85–116.PubMedCrossRefGoogle Scholar
  3. 3.
    Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review [see comment]. [erratum appears in Bipolar Disord 2007 May;9(3):314]. Bipolar Disord 2006 Oct;8(5 Pt 2):625–39.Google Scholar
  4. 4.
    Malhi GS, Adams D, Berk M. Is lithium in a class of its own? A brief profile of its clinical use. Aust N Z J Psychiatry. 2009;43:1093–104.Google Scholar
  5. 5.
    Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290(11):1467–73.PubMedCrossRefGoogle Scholar
  6. 6.
    Bowden CL. Bipolar pathophysiology and development of improved treatments. Brain Res. 2008;1235:92–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Manji HK, Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry. 2002;7(Suppl. 1):S46–56.PubMedCrossRefGoogle Scholar
  8. 8.
    Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol. 2009;12(4):441–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Quiroz JA, Machado-Vieira R, Zarate JCA, et al. Novel insights into lithium’s mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology. 2010;62(1):50–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Post RM, Speer AM, Hough CJ, et al. Neurobiology of bipolar illness: implications for future study and therapeutics. Ann Clin Psychiatry. 2003;15(2):85–94.PubMedCrossRefGoogle Scholar
  11. 11.
    Chen G, Rajkowska G, Du F, et al. Enhancement of hippocampal neurogenesis by lithium. J Neurochem. 2000;75(4):1729–34.PubMedCrossRefGoogle Scholar
  12. 12.
    Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience Biobehav Rev. 2011;35(3):804–17.CrossRefGoogle Scholar
  13. 13.
    Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry. 2000;57(2):187–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Bowden CL, Mosolov S, Hranov L, et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Int Clin Psychopharmacol. 2010;25(2):60–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Yildiz A, Vieta E, Leucht S, et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36(2):375–89.PubMedCrossRefGoogle Scholar
  16. 16.
    Shafti SS. Olanzapine vs. lithium in management of acute mania. J Affect Disord. 2010;122(3):273–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol. 1998;21(3):176–80.PubMedGoogle Scholar
  18. 18.
    Gershon S, Chengappa KR, Malhi GS. Lithium specificity in bipolar illness: a classic agent for a classic disorder. Bipolar Disord. 2009;11(Suppl. 2):34–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161(2):217–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306–15.PubMedCrossRefGoogle Scholar
  21. 21.
    Berk M, Malhi GS. Should antipsychotics take pole position in mania treatment? Lancet. 2011;378(9799):1279–81.PubMedCrossRefGoogle Scholar
  22. 22.
    National Institute for Health and Clinical Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care: clinical guideline 38. London: National Institute for Health and Clinical Excellence; 2006.Google Scholar
  23. 23.
    Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7(Suppl.3):5–69.PubMedCrossRefGoogle Scholar
  24. 24.
    Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8(6):721–39.PubMedCrossRefGoogle Scholar
  25. 25.
    Malhi GS, Adams DA, Lampe L, et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand. 2009;119(Suppl. 439):27–46.CrossRefGoogle Scholar
  26. 26.
    Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59(1):62–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Bhagwagar Z, Goodwin GM. The role of lithium in the treatment of bipolar depression. Clin Neurosci Res. 2002;2(3–4):222–7.CrossRefGoogle Scholar
  28. 28.
    Van Lieshout RJ, MacQueen GM. Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. Br J Psychiatry. 2010;196(4):266–73.PubMedCrossRefGoogle Scholar
  29. 29.
    Fountoulakis KN. An update of evidence-based treatment of bipolar depression: where do we stand? Curr Opin Psychiatry. 2010;23(1):19–24.PubMedCrossRefGoogle Scholar
  30. 30.
    Fountoulakis KN, Grunze H, Panagiotidis P, et al. Treatment of bipolar depression: an update. J Affect Disord. 2008;109(1–2):21–34.PubMedCrossRefGoogle Scholar
  31. 31.
    Vieta E, Locklear J, Gunther O, et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Pyschopharmacol. 2010;30:579–90.CrossRefGoogle Scholar
  32. 32.
    Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach. Part I: clinical efficacy in bipolar disorder. CNS Drugs. 2009;23(3):225–40.PubMedCrossRefGoogle Scholar
  33. 33.
    Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–55.PubMedCrossRefGoogle Scholar
  34. 34.
    Young AH, Hammond JM. Lithium in mood disorders: increasing evidence base, declining use? Br J Psychiatry. 2007;191:474–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Coryell W. Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. Bipolar Disord. 2009;11:77–83.PubMedCrossRefGoogle Scholar
  36. 36.
    Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385–95.PubMedCrossRefGoogle Scholar
  37. 37.
    Silverstone T. Is lithium still the maintenance treatment of choice for bipolar disorder? CNS Drugs. 2000;14(2):81–94.CrossRefGoogle Scholar
  38. 38.
    Perlis R, Sachs G, Lafer B, et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry. 2002;159(7):1155–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Cavanagh J, Smyth R, Goodwin GM. Relapse into mania or depression following lithium discontinuation: a 7-year follow-up. Acta Psychiatr Scand. 2004;109(2):91–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Klein E, Lavie P, Meiraz R, et al. Increased motor activity and recurrent manic episodes: predictors of rapid relapse in remitted bipolar disorder patients after lithium discontinuation. Biol Psychiatry. 1992;31(3):279–84.PubMedCrossRefGoogle Scholar
  41. 41.
    Bowden C, Gögüs A, Grunze H, et al. A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. Int Clin Psychopharmacol. 2008;23(5):254–62.PubMedCrossRefGoogle Scholar
  42. 42.
    Malhi GS, Adams D, Cahill CM, et al. The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice. Drugs. 2009;69(15):2063–101.PubMedCrossRefGoogle Scholar
  43. 43.
    Bowden CL. The ability of lithium and other mood stabilisers to decrease suicide risk and prevent relapse. Curr Psychiatr Rep. 2000;2:490–4.CrossRefGoogle Scholar
  44. 44.
    Muller-Oerlinghausen B. Arguments for the specificity of the antisuicidal effect of lithium. Eur Arch Psychiatry Clin Neurosci. 2001;251(Suppl. 2)):II/72–5.Google Scholar
  45. 45.
    Cipriani A, Pretty H, Hawton K, et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials [see comment]. Am J Psychiatry. 2005;162(10):1805–19.PubMedCrossRefGoogle Scholar
  46. 46.
    Wingo AP, Wingo TS, Harvey PD, et al. Effects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry. 2009;70(11):1588–97.PubMedCrossRefGoogle Scholar
  47. 47.
    Engelsmann F, Katz J, Ghadirian AM, et al. Lithium and memory: a long term follow-up study. J Clin Psychopharmacol. 1988;8(3):207–12.PubMedCrossRefGoogle Scholar
  48. 48.
    Smigan L, Perris C. Memory functions and prophylactic lithium treatment. Psychol Med. 1983;13:529–36.PubMedCrossRefGoogle Scholar
  49. 49.
    Pachet AK, Wisniewski AM. The effects of lithium on cognition: an updated review. Psychopharmacology (Berl). 2003;170:225–34.CrossRefGoogle Scholar
  50. 50.
    Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord. 2010;12(1):87–94.PubMedCrossRefGoogle Scholar
  51. 51.
    Arts B, Jabben N, Krabbendam L, et al. A 2-year naturalistic study on cognitive functioning in bipolar disorder. Acta Psychiatr Scand. 2011;123(3):190–205.PubMedCrossRefGoogle Scholar
  52. 52.
    Rybakowski JK, Permoda-Osip A, Borkowska A. Response to prophylactic lithium in bipolar disorder may be associated with a preservation of executive cognitive functions. Eur Neuropsychopharmacol. 2009;19(11):791–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Anand A, Shekhar A. Brain imaging studies in mood and anxiety disorders. Ann N Y Acad Sci. 2003;985(1):370–88.PubMedCrossRefGoogle Scholar
  54. 54.
    Bell EC, Willson MC, Wilman AH, et al. Differential effects of chronic lithium and valproate on brain activation in healthy volunteers. Hum Psychopharmacol Clin Exp. 2005;20(6):415–24.CrossRefGoogle Scholar
  55. 55.
    Bell EC, Willson MC, Wilman AH, et al. Lithium and valproate attenuate dextroamphetamine-induced changes in brain activation. Hum Psychopharmacol. 2005;20(2):87–96.PubMedCrossRefGoogle Scholar
  56. 56.
    Silverstone PH, Bell EC, Willson MC, et al. Lithium alters brain activation in bipolar disorder in a task- and state-dependent manner: an fMRI study. Ann Gen Psychiatry. 2005;4(14):1–7.Google Scholar
  57. 57.
    Tsaltas E, Kontis D, Boulougouris V, et al. Lithium and cognitive enhancement: leave it or take it? Psychopharmacology (Berl). 2009;202(1–3):457–76.CrossRefGoogle Scholar
  58. 58.
    Emsell L, McDonald C. The structural neuroimaging of bipolar disorder. Int Rev Psychiatry. 2009;21(4):297–313.PubMedCrossRefGoogle Scholar
  59. 59.
    Kempton MJ, Geddes JR, Ettinger U, et al. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry. 2008;65(9):1017–32.PubMedCrossRefGoogle Scholar
  60. 60.
    Strakowski SM, DelBello MP, Adler CM. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry. 2005;10:105–16.PubMedCrossRefGoogle Scholar
  61. 61.
    Hajek T, Cullis J, Novak T, et al. Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord. 2012;14(3):261–70.PubMedCrossRefGoogle Scholar
  62. 62.
    Chepenik LG, Wang F, Spencer L, et al. Structure-function associations in hippocampus in bipolar disorder. Biol Psychol. 2012;90(1):18–22.PubMedCrossRefGoogle Scholar
  63. 63.
    Savitz J, Nugent AC, Bogers W, et al. Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage. 2010;49(4):2966–76.PubMedCrossRefGoogle Scholar
  64. 64.
    Foland-Ross LC. Brooks Iii JO, Mintz J, et al. Mood-state effects on amygdala volume in bipolar disorder. J Affect Disord. 2012;139(3):298–301.PubMedCrossRefGoogle Scholar
  65. 65.
    Hajek T, Gunde E, Slaney C, et al. Striatal volumes in affected and unaffected relatives of bipolar patients: high-risk study. J Psychiatr Res. 2009;43(7):724–9.PubMedCrossRefGoogle Scholar
  66. 66.
    DelBello MP, Zimmerman ME, Mills NP, et al. Magnetic resonance imaging analysis of amygdala and other subcortical brain regions in adolescents with bipolar disorder. Bipolar Disord. 2004;6(1):43–52.PubMedCrossRefGoogle Scholar
  67. 67.
    Strakowski SM, DelBello MP, Zimmerman ME, et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am J Psychiatry. 2002;159:1841–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Drevets WC, Price JL, Simpson JR, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386(6627):824–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Sassi RB, Brambilla P, Hatch JP, et al. Reduced left anterior cingulate volumes in untreated bipolar patients. Biol Psychiatry. 2004;56(7):467–75.PubMedCrossRefGoogle Scholar
  70. 70.
    López-Larson MP, DelBello MP, Zimmerman ME, et al. Regional prefrontal gray and white matter abnormalities in bipolar disorder. Biol Psychiatry. 2002;52(2):93–100.PubMedCrossRefGoogle Scholar
  71. 71.
    Brooks JO 3rd, Bonner JC, Rosen AC, et al. Dorsolateral and dorsomedial prefrontal gray matter density changes associated with bipolar depression. Psychiatry Res. 2009;172(3):200–4.PubMedCrossRefGoogle Scholar
  72. 72.
    Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord. 2002;4(2):105–16.PubMedCrossRefGoogle Scholar
  73. 73.
    Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry. 2001;49(9):741–52.PubMedCrossRefGoogle Scholar
  74. 74.
    Öngür D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci. 1998;95(22):13290–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Brambilla P, Nicoletti MA, Harenski K, et al. Anatomical MRI study of subgenual prefrontal cortex in bipolar and unipolar subjects. Neuropsychopharmacology. 2002;27(5):792–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Fornito A, Malhi GS, Lagopoulos J, et al. Anatomical abnormalities of the anterior cingulate and paracingulate cortex in patients with bipolar I disorder. Psychiatry Res Neuroimaging. 2008;162(2):123–32.CrossRefGoogle Scholar
  77. 77.
    Brambilla P, Harenski K, Nicoletti M, et al. Differential effects of age on brain gray matter in bipolar patients and healthy individuals. Neuropsychobiology. 2001;43(4):242–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Bearden CE, Thompson PM, Dalwani M, et al. Greater cortical gray matter density in lithium-treated patients with bipolar disorder [see comment]. Biol Psychiatry. 2007;62(1):7–16.PubMedCrossRefGoogle Scholar
  79. 79.
    Sassi RB, Nicoletti M, Brambilla P, et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett. 2002;329(2):243–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Adler CM, Levine AD, DelBello MP, et al. Changes in gray matter volume in patients with bipolar disorder. Biol Psychiatry. 2005;58(2):151–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Takahashi T, Malhi GS, Wood SJ, et al. Gray matter reduction of the superior temporal gyrus in patients with established bipolar I disorder. J Affect Disord. 2010;123:276–82.PubMedCrossRefGoogle Scholar
  82. 82.
    Usher J, Menzel P, Schneider-Axmann T, et al. Increased right amygdala volume in lithium-treated patients with bipolar I disorder. Acta Psychiatr Scand. 2010;121:119–24.PubMedCrossRefGoogle Scholar
  83. 83.
    Foland LC, Altshuler LL, Sugar CA, et al. Increased volume of the amygdala and hippocampus in bipolar patients treated with lithium. Neuroreport. 2008;19(2):221–4.PubMedCrossRefGoogle Scholar
  84. 84.
    Hallahan B, Newell J, Soares JC, et al. Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data. Biol Psychiatry. 2011;69(4):326–35.PubMedCrossRefGoogle Scholar
  85. 85.
    van Erp TGM, Thompson PM, Kieseppä T, et al. Hippocampal morphology in lithium and non-lithium-treated bipolar I disorder patients, non-bipolar co-twins, and control twins. Hum Brain Mapp. 2012;33(3):501–10.PubMedCrossRefGoogle Scholar
  86. 86.
    Yucel K, Taylor VH, McKinnon MC, et al. Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment. Neuropsychopharmacology. 2008;33(2):361–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Moore GJ, Cortese BM, Glitz DA, et al. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry. 2009;70(5):699–705.PubMedCrossRefGoogle Scholar
  88. 88.
    Schildkraut JJ. The catecholamine hypothesis of affective-disorders: a review of supporting evidence. Am J Psychiatry. 1965;122(5):509–22.PubMedGoogle Scholar
  89. 89.
    Pert A, Rosenblatt JE, Sivit C, et al. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science. 1978;201(4351):171–3.PubMedCrossRefGoogle Scholar
  90. 90.
    Knapp S, Mandell AJ. Short- and long-term lithium administration: effects on the brain’s serotonergic biosynthetic systems. Science. 1973;180(4086):645–7.PubMedCrossRefGoogle Scholar
  91. 91.
    Belmaker RH. Bipolar disorder. N Engl J Med. 2004;351(5):476–86.PubMedCrossRefGoogle Scholar
  92. 92.
    Berk M, Dodd S, Kauer-Sant’Anna M, et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand. 2007;116(Suppl. 434):41–9.CrossRefGoogle Scholar
  93. 93.
    Cousins DA, Butts K, Young AH. The role of dopamine in bipolar disorder. Bipolar Disord. 2010;11:787–806.CrossRefGoogle Scholar
  94. 94.
    Jacobs D, Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med. 1986;16(02):323–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Post RM, Jimerson DC, Bunney WE, et al. Dopamine and mania: behavioral and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology (Berl). 1980;67(3):297–305.CrossRefGoogle Scholar
  96. 96.
    Staunton DA, Magistretti PJ, Shoemaker WJ, et al. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum: I. Locomotor activity and behavioral supersensitivity. Brain Res. 1982;232(2):391–400.PubMedCrossRefGoogle Scholar
  97. 97.
    Gambarana C, Ghiglieri O, Masi F, et al. The effects of long-term administration of rubidium or lithium on reactivity to stress and on dopamine output in the nucleus accumbens in rats. Brain Res. 1999;826(2):200–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Ichikawa J, Dai J, Meltzer HY. Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: role of 5-HT1A receptor antagonism. Brain Res. 2005;1049:182–90.PubMedCrossRefGoogle Scholar
  99. 99.
    Ferrie L, Young AH, McQuade R. Effect of lithium and lithium withdrawal on potassium-evoked dopamine release and tyrosine hydroxylase expression in the rat. Int J Neuropsychopharmacol. 2006;9(6):729–35.PubMedCrossRefGoogle Scholar
  100. 100.
    Ferrie L, Young AH, McQuade R. Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat. J Psychopharmacol (Oxf). 2005;19(3):229–34.CrossRefGoogle Scholar
  101. 101.
    Malhi GS, Tanious M, Gershon S. The lithiumeter: a measured approach. Bipolar Disord. 2011;13(3):219–26.PubMedCrossRefGoogle Scholar
  102. 102.
    Manji HK, Lenox RH. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry. 2000;48(6):518–30.PubMedCrossRefGoogle Scholar
  103. 103.
    Michael N, Erfurth A, Ohrmann P, et al. Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology (Berl). 2003;168(3):344–6.CrossRefGoogle Scholar
  104. 104.
    Öngür D, Jensen JE, Prescot AP, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008;64(8):718–26.PubMedCrossRefGoogle Scholar
  105. 105.
    Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsychopharmacol. 1999;9(Suppl. 4):S119–23.PubMedCrossRefGoogle Scholar
  106. 106.
    Tsapakis EM, Travis MJ. Glutamate and psychiatric disorders. Adv Psychiatr Treat. 2002;8:189–97.CrossRefGoogle Scholar
  107. 107.
    Hokin LE, Dixon JF, Los GV. A novel action of lithium: stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl d-aspartate receptor in monkey and mouse cerebral cortex slices. Adv Enzyme Regul. 1996;36:229–44.PubMedCrossRefGoogle Scholar
  108. 108.
    Ghasemi M, Dehpour AR. The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. Trends Pharmacol Sci. 2011;32(7):420–34.PubMedCrossRefGoogle Scholar
  109. 109.
    Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA. 1998;95(14):8363–8.PubMedCrossRefGoogle Scholar
  110. 110.
    Brunello N, Tascedda F. Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int J Neuropsychopharmacol. 2003;6(2):181–9.PubMedCrossRefGoogle Scholar
  111. 111.
    Hashimoto R, Takei N, Shimazu K, et al. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology. 2002;43(7):1173–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Nonaka S, Hough CJ, Chuang D-M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-d-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA. 1998;95(5):2642–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Bown CD, Wang JF, Young LT. Attenuation of N-methyl-d-aspartate-mediated cytoplasmic vacuolization in primary rat hippocampal neurons by mood stabilizers. Neuroscience. 2003;117(4):949–55.PubMedCrossRefGoogle Scholar
  114. 114.
    Ng WXD, Lau IY, Graham S, Sim K. Neurobiological evidence for thalamic, hippocampal and related glutamatergic abnormalities in bipolar disorder: a review and synthesis. Neurosci Biobehav Rev. 2009;33(3):336–54.PubMedCrossRefGoogle Scholar
  115. 115.
    Brambilla P, Perez J, Barale F, et al. GABAergic dysfunction in mood disorders. Mol Psychiatry. 2003;8(8):721–37.PubMedCrossRefGoogle Scholar
  116. 116.
    Kato T. Molecular neurobiology of bipolar disorder: a disease of ‘mood-stabilizing neurons’? Trends Neurosci. 2008;31(10):495–503.PubMedCrossRefGoogle Scholar
  117. 117.
    Lenox RH, McNamara RK, Papke RL, et al. Neurobiology of lithium: an update. J Clin Psychiatry. 1998;59(Suppl. 6):37–47.PubMedGoogle Scholar
  118. 118.
    Shiah I, Yatham L. GABA function in mood disorders: an update and critical review. Life Sci. 1998;63(15):1289–303.PubMedCrossRefGoogle Scholar
  119. 119.
    Petty F. Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease? Clin Chem. 1994;40(2):296–302.PubMedGoogle Scholar
  120. 120.
    Chuang D-M, Chen R-W, Chalecka-Franaszek E, et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord. 2002;4(2):129–36.PubMedCrossRefGoogle Scholar
  121. 121.
    Ahluwalia P, Grewaal DS, Singhal RL. Brain gabaergic and dopaminergic systems following lithium treatment and withdrawal. Prog Neuropsychopharmacol. 1981;5(5–6):527–30.PubMedCrossRefGoogle Scholar
  122. 122.
    Vargas C, Tannhauser M, Barros HMT. Dissimilar effects of lithium and valproic acid on GABA and glutamine concentrations in rat cerebrospinal fluid. Gen Pharmacol Vasc Syst. 1998;30(4):601–4.CrossRefGoogle Scholar
  123. 123.
    Schloesser RJ, Huang J, Klein PS, et al. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 2008;33:110–33.PubMedCrossRefGoogle Scholar
  124. 124.
    Manji HK, Lenox RH. The nature of bipolar disorder. J Clin Psychiatry. 2000;61(Suppl. 13):42–57.PubMedGoogle Scholar
  125. 125.
    Gould TD, Chen G, Manji HK. Mood stabilizer psychopharmacology. Clin Neurosci Res. 2002;2(3–4):193–212.PubMedCrossRefGoogle Scholar
  126. 126.
    Marmol F. Lithium: bipolar disorder and neurodegenerative diseases. Possible cellular mechanisms of the therapeutic effects of lithium. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1761–71.PubMedCrossRefGoogle Scholar
  127. 127.
    Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry. 1999;4:117–28.PubMedCrossRefGoogle Scholar
  128. 128.
    Montezinho LP, Mørk A, Duarte CB, et al. Effects of mood stabilizers on the inhibition of adenylate cyclase via dopamine D2-like receptors. Bipolar Disord. 2007;9(3):290–7.PubMedCrossRefGoogle Scholar
  129. 129.
    Jope RS. A bimodal model of the mechanism of action of lithium. Mol Psychiatry. 1999;4(1):21–5.PubMedCrossRefGoogle Scholar
  130. 130.
    Mann L, Heldman E, Bersudsky Y, et al. Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their anti-depressant effect. Bipolar Disord. 2009;11:885–96.PubMedCrossRefGoogle Scholar
  131. 131.
    Ikonomov OC, Manji HK. Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Am J Psychiatry. 1999;156(10):1506–14.PubMedGoogle Scholar
  132. 132.
    Machado-Vieira R, Manji HK, Zarate CA Jr, et al. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 2009;11(Suppl. 2):92–109.PubMedCrossRefGoogle Scholar
  133. 133.
    Silverstone PH, McGrath BM. Lithium and valproate and their possible effects on the myo-inositol second messenger system in healthy volunteers and bipolar patients. Int Rev Psychiatry. 2009;21(4):414–23.PubMedCrossRefGoogle Scholar
  134. 134.
    Calker Dv, Belmaker RH. The high affinity inositol transport system: implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disord. 2000;2(2):102–7.PubMedCrossRefGoogle Scholar
  135. 135.
    Willmroth F, Drieling T, Lamla U, et al. Sodium-myo-inositol co-transporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar 1 disorder and down-regulated under treatment with mood stabilizers. Int J Neuropsychopharmacol. 2007;10(1):63–71.PubMedCrossRefGoogle Scholar
  136. 136.
    Deranieh RM, Greenberg ML. Cellular consequences of inositol depletion. Biochem Soc Trans. 2009;37:1099–103.PubMedCrossRefGoogle Scholar
  137. 137.
    Berridge MJ. Inositol trisphosphate and diacylglycerol as second messengers. Biochem J. 1984;220:345–60.PubMedGoogle Scholar
  138. 138.
    Lenox RH, Wang L. Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol Psychiatry. 2003;8(2):135–44.PubMedCrossRefGoogle Scholar
  139. 139.
    Silverstone PH, McGrath BM, Kim H, et al. Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord. 2005;7(1):1–10.PubMedCrossRefGoogle Scholar
  140. 140.
    Chen G, Hasanat KA, Bebchuk JM, et al. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med. 1999;61(5):599–617.PubMedGoogle Scholar
  141. 141.
    Davanzo P, Thomas MA, Yue K, et al. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology. 2001;24(4):359–69.PubMedCrossRefGoogle Scholar
  142. 142.
    Moore GJ, Bebchuk JM, Parrish JK, et al. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am J Psychiatry. 1999;156(12):1902–8.PubMedGoogle Scholar
  143. 143.
    Chiu CT, Chuang DM. Neuroprotective action of lithium in disorders of the central nervous system. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011;36(6):461–76.PubMedGoogle Scholar
  144. 144.
    Zarate CA, Manji HK. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs. 2009;23(7):569–82.PubMedCrossRefGoogle Scholar
  145. 145.
    Hahn C-G, Friedman E. Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord. 1999;1(2):81–6.PubMedCrossRefGoogle Scholar
  146. 146.
    Szabo ST, Machado-Vieira R, Yuan P, et al. Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology. 2009;56(1):47–55.PubMedCrossRefGoogle Scholar
  147. 147.
    Manji HK, Etcheberrigaray R, Chen G, et al. Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the α isozyme. J Neurochem. 1993;61(6):2303–10.PubMedCrossRefGoogle Scholar
  148. 148.
    Lenox RH, Watson DG, Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res. 1992;570:333–40.PubMedCrossRefGoogle Scholar
  149. 149.
    Friedman E, Hoau Yan W, Levinson D, et al. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry. 1993;33(7):520–5.PubMedCrossRefGoogle Scholar
  150. 150.
    Warsh JJ, Andreopoulos S, Li PP. Role of intracellular calcium signaling in the pathophysiology and pharmacotherapy of bipolar disorder: current status. Clin Neurosci Res. 2004;4(3–4):201–13.CrossRefGoogle Scholar
  151. 151.
    Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4(7):517–29.PubMedCrossRefGoogle Scholar
  152. 152.
    Carafoli E, Santella L, Branca D, et al. Generation, control, and processing of cellular calcium signals. Crit Rev Biochem Mol Biol. 2001;36(2):107–260.PubMedCrossRefGoogle Scholar
  153. 153.
    Berk M, Plein H, Ferreira D. Platelet glutamate receptor supersensitivity in major depressive disorder. Clin Neuropharmacol. 2001;24(3):129–32.PubMedCrossRefGoogle Scholar
  154. 154.
    Berk M, Plein H, Belsham B. The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. Life Sci. 2000;66(25):2427–32.PubMedCrossRefGoogle Scholar
  155. 155.
    Plein H, Berk M. Changes in the platelet intracellular calcium response to serotonin in patients with major depression treated with electroconvulsive therapy: state or trait marker status. Int Clin Psychopharmacol. 2000;15(2):93–8.PubMedCrossRefGoogle Scholar
  156. 156.
    Berk M, Kirchmann NH, Butkow N. Lithium blocks 45Ca2+ uptake into platelets in bipolar affective disorder and controls. Clin Neuropharmacol. 1996;19(1):48–51.PubMedCrossRefGoogle Scholar
  157. 157.
    Sourial-Bassillious N, Rydelius PA, Aperia A, et al. Glutamate-mediated calcium signaling: a potential target for lithium action. Neuroscience. 2009;161(4):1126–34.PubMedCrossRefGoogle Scholar
  158. 158.
    Perova T, Kwan M, Li PP, et al. Differential modulation of intracellular Ca2+ responses in B lymphoblasts by mood stabilizers. Int J Neuropsychopharmacol. 2010;13(06):693–702.PubMedCrossRefGoogle Scholar
  159. 159.
    Crespo-Biel N, Camins A, Canudas AM, et al. Kainate-induced toxicity in the hippocampus: potential role of lithium. Bipolar Disord. 2010;12(4):425–36.PubMedCrossRefGoogle Scholar
  160. 160.
    Camins A, Crespo-Biel N, Junyent F, et al. Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium. Curr Drug Metab. 2009;10(5):433–47.PubMedCrossRefGoogle Scholar
  161. 161.
    Chang K, Barnea-Goraly N, Karchemskiy A, et al. Cortical magnetic resonance imaging findings in familial pediatric bipolar disorder. Biol Psychiatry. 2005;58(3):197–203.PubMedCrossRefGoogle Scholar
  162. 162.
    Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord. 2002;4:105–16.PubMedCrossRefGoogle Scholar
  163. 163.
    Mielke K, Herdegen T. JNK and p38 stress kinases: degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol. 2000;61(1):45–60.PubMedCrossRefGoogle Scholar
  164. 164.
    Chen R-W, Qin Z-H, Ren M, et al. Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. J Neurochem. 2003;84(3):566–75.PubMedCrossRefGoogle Scholar
  165. 165.
    Chiu C-T, Chuang D-M. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther. 2010;128(2):281–304.PubMedCrossRefGoogle Scholar
  166. 166.
    Chen R-W, Chuang D-M. Long-term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. J Biol Chem. 1999;274(10):6039–42.PubMedCrossRefGoogle Scholar
  167. 167.
    Berk M, Conus P, Kapczinski F, et al. From neuroprogression to neuroprotection: implications for clinical care. Med J Aust. 2010;193(4):S36–40.PubMedGoogle Scholar
  168. 168.
    Ng F, Berk M, Dean OM, et al. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11:851–76.PubMedCrossRefGoogle Scholar
  169. 169.
    Machado-Vieira R, Pivovarova NB, Stanika RI, et al. The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biol Psychiatry. 2011;69(4):344–52.PubMedCrossRefGoogle Scholar
  170. 170.
    Scola G, Kim HK, Young LT, et al. A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. Biol Psychiatry. 2013;73:e4–5.PubMedCrossRefGoogle Scholar
  171. 171.
    Maurer IC, Schippel P, Volz H-P. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord. 2009;11(5):515–22.PubMedCrossRefGoogle Scholar
  172. 172.
    Eskandari M, Fard J, Hosseini M-J, et al. Glutathione mediated reductive activation and mitochondrial dysfunction play key roles in lithium induced oxidative stress and cytotoxicity in liver. Biometals. 2012;25(5):863–73.PubMedCrossRefGoogle Scholar
  173. 173.
    Berk M, Ng F, Dean O, et al. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci. 2008;29(7):346–51.PubMedCrossRefGoogle Scholar
  174. 174.
    Frey BN, Martins MR, Petronilho FC, et al. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord. 2006;8(3):275–80.PubMedCrossRefGoogle Scholar
  175. 175.
    Andreazza AC, Kapczinski F, Kauer-Sant’Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34(4):263–71.PubMedGoogle Scholar
  176. 176.
    Andreazza AC, Shao L, Wang J-F, et al. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry. 2010;67(4):360–8.PubMedCrossRefGoogle Scholar
  177. 177.
    Andreazza AC, Cassini C, Rosa AR, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res. 2007;41(6):523–9.PubMedCrossRefGoogle Scholar
  178. 178.
    Cecil KM, DelBello MP, Morey R, et al. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord. 2002;4(6):357–65.PubMedCrossRefGoogle Scholar
  179. 179.
    Frey BN, Valvassori SS, Reus GZ, et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci. 2006;31(5):326–32.PubMedGoogle Scholar
  180. 180.
    Machado-Vieira R, Andreazza AC, Viale CI, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett. 2007;421(1):33–6.PubMedCrossRefGoogle Scholar
  181. 181.
    Cunha ABM, Frey BN, Andreazza AC, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett. 2006;398(3):215–9.PubMedCrossRefGoogle Scholar
  182. 182.
    Tramontina JF, Andreazza AC, Kauer-Sant’Anna M, et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett. 2009;452(2):111–3.PubMedCrossRefGoogle Scholar
  183. 183.
    Einat H, Manji HK, Einat H, et al. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry. 2006;59(12):1160–71.PubMedCrossRefGoogle Scholar
  184. 184.
    Rybakowski JK, Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol. 2010;13:617–22.PubMedCrossRefGoogle Scholar
  185. 185.
    Vidal F, de Araujo WM, Cruz AL, et al. Lithium reduces tumorigenic potential in response to EGF signaling in human colorectal cancer cells. Int J Oncol. 2011;38(5):1365–73.PubMedGoogle Scholar
  186. 186.
    Cameron AR, Anil S, Sutherland E, et al. Zinc-dependent effects of small molecules on the insulin-sensitive transcription factor FOXO1a and gluconeogenic genes. Metallomics. 2010;2(3):195–203.PubMedCrossRefGoogle Scholar
  187. 187.
    Manji HK, Moore GJ, Chen G. Lithium up-regulates the cytoprotective protein bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry. 2000;61(Suppl. 9):82–96.PubMedGoogle Scholar
  188. 188.
    Lien R, Flaisher-Grinberg S, Cleary C, et al. Behavioral effects of Bcl-2 deficiency: implications for affective disorders. Pharmacol Rep. 2008;60(4):490–8.PubMedGoogle Scholar
  189. 189.
    Chang YC, Rapoport SI, Rao JS. Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochem Res. 2009;34(3):536–41.PubMedCrossRefGoogle Scholar
  190. 190.
    Ghribi O, Herman MM, Spaulding NK, et al. Lithium inhibits aluminum-induced apoptosis in rabbit hippocampus, by preventing cytochrome c translocation, Bcl-2 decrease, Bax elevation and caspase-3 activation. J Neurochem. 2002;82(1):137–45.PubMedCrossRefGoogle Scholar
  191. 191.
    Beaulieu J-M, Sotnikova TD, Yao W-D, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA. 2004;101(14):5099–104.PubMedCrossRefGoogle Scholar
  192. 192.
    Prickaerts J, Moechars D, Cryns K, et al. Transgenic mice overexpressing glycogen synthase kinase 3β: a putative model of hyperactivity and mania. J Neurosci. 2006;26(35):9022–9.PubMedCrossRefGoogle Scholar
  193. 193.
    Klein E, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci. 1996;93(16):8455–9.PubMedCrossRefGoogle Scholar
  194. 194.
    Li X, Friedman AB, Zhu W, et al. Lithium regulates glycogen synthase kinase-3β in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry. 2007;61(2):216–22.PubMedCrossRefGoogle Scholar
  195. 195.
    Tajes M, Yeste-Velasco M, Zhu X, et al. Activation of Akt by lithium: pro-survival pathways in aging. Mech Ageing Dev. 2009;130:253–61.PubMedCrossRefGoogle Scholar
  196. 196.
    Freland L, Beaulieu J-M. Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci. 2012;5:14.PubMedCrossRefGoogle Scholar
  197. 197.
    Rowe MK, Wiest C, Chuang D-M. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev. 2007;31(6):920–31.PubMedCrossRefGoogle Scholar
  198. 198.
    Gould TD, Einat H, Bhat R, et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol. 2004;7:387–90.PubMedCrossRefGoogle Scholar
  199. 199.
    Silva R, Mesquita AR, Bessa J, et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3β. Neuroscience. 2008;152(3):656–69.PubMedCrossRefGoogle Scholar
  200. 200.
    Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3β, β-catenin, and neurotrophin cascades. J Pharmacol Sci. 2009;110(1):14–28.PubMedCrossRefGoogle Scholar
  201. 201.
    Maiuri MC, Zalckvar E, Kimchi A, et al. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol. 2007;8(9):741–52.PubMedCrossRefGoogle Scholar
  202. 202.
    Meléndez A, Neufeld TP. The cell biology of autophagy in metazoans: a developing story. Development. 2008;135(14):2347–60.PubMedCrossRefGoogle Scholar
  203. 203.
    Sarkar S, Krishna G, Imarisio S, et al. A rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin. Hum Mol Genet. 2008;17(2):170–8.PubMedCrossRefGoogle Scholar
  204. 204.
    Sarkar S, Floto RA, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol. 2005;170(7):1101–11.PubMedCrossRefGoogle Scholar
  205. 205.
    Heiseke A, Aguib Y, Schatzl HM. Autophagy, prion infection and their mutual interactions. Curr Issues Mol Biol. 2009;12:87–98.PubMedGoogle Scholar
  206. 206.
    Camins A, Verdaguer E, Junyent F, et al. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci Ther. 2009;15(4):333–44.PubMedCrossRefGoogle Scholar
  207. 207.
    Dean OM, Bush AI, Berk M. Translating the rosetta stone of N-acetylcysteine. Biol Psychiatry. 2012;71(11):935–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Gin S. Malhi
    • 1
    • 2
    Email author
  • Michelle Tanious
    • 1
    • 2
  • Pritha Das
    • 1
    • 2
  • Carissa M. Coulston
    • 1
    • 2
  • Michael Berk
    • 3
    • 4
  1. 1.Discipline of Psychiatry, Sydney Medical SchoolUniversity of SydneySydneyAustralia
  2. 2.CADE Clinic, Department of PsychiatryRoyal North Shore HospitalSydneyAustralia
  3. 3.Deakin UniversitySchool of Medicine, Barwon HealthGeelongAustralia
  4. 4.Orygen Youth Health Research Centre, Mental Health Research Institute and Department of PsychiatryUniversity of MelbourneParkvilleAustralia

Personalised recommendations